Video

Don't Write Off Immunotherapy in Brain Cancer Just Yet

Researchers should not give up hope in using immunotherapy to treat brain cancers.

Although negative results from trials evaluating immunotherapy and brain cancer were presented at the 2018 American Society of Clinical Oncology (ASCO) annual meeting, David Reardon, M.D., clinical director for the Center for Neuro-Oncology, Medical Oncology at the Dana-Farber Cancer Institute and associate professor of Medicine at Harvard Medical School, says that we shouldn’t write off the possibility of this treatment regimen just yet.

Brain cancers like glioblastoma (GBM) are notoriously difficult to treat, so it is going to take more research and hard work to determine how these agents can fit into the arsenal for treating GBM, he added.

Related Videos
Dr. Alan Tan is a genitourinary oncology (GU) and melanoma specialist at the Vanderbilt-Ingram Cancer Center in Nashville, Tennessee; an associate professor of medicine in the Division of Hematology and Oncology at Vanderbilt University Medical Center; and GU Executive Officer with the Alliance for Clinical Trials in Oncology.
Dr. Chandler Park, a medical oncologist of Genitourinary Medical Oncology, at the Norton Healthcare Institute, in Louisville, Kentucky.
Image of woman with blonde hair.
Image of woman with blonde hair.
Image of woman with brown hair.
Image of woman.
Dr. Andreas M. Kaiser is a professor and chief of the Division of Colorectal Surgery in the Department of Surgery at City of Hope comprehensive cancer center in Duarte, California.
Dr. Guru Sonpavde emphasized the importance of better understanding how genetic mutations influence the treatment of cancer care, particularly GU cancers.
Related Content